{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:24:12Z","timestamp":1787293452085,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rashes in patients treated with epidermal growth factor receptor inhibitors (EGFRIs) are closely related to better clinical outcomes. Multiple randomized controlled trials have evaluated rashes caused by EGFRIs. We conducted a meta-analysis of patients with tumors receiving EGFR-targeted therapy to determine the incidence and relative risk of rashes associated with these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four databases (PubMed, Web of Science, Embase, and Cochrane) were systematically searched to find randomized controlled trials reporting the incidence of rash associated with EGFRIs from the time of database construction to May 15, 2025. Meta-analysis was used to calculate the total incidence and relative risk (RR) of all grades or each grade of rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 65,116 patients from 194 studies were included. The pooled incidences of all-grade rash and high-grade rash associated with EGFRIs were 52.30% (95% CI: 48.70%-55.80%) and 9.50% (95% CI: 8.70%-10.30%), respectively. The pooled RR suggested that EGFRIs were associated with a significantly increased risk of rash. Subgroup analysis and regression analysis showed that Asian populations, EGFR monoclonal antibodies (EGFR mAbs), phase III clinical trials, and EGFRI combination therapy may increase the occurrence of rash, whereas Aumolertinib had a significantly lower RR of rash. The type of tumor and the year of publication had no significant effect on the incidence of rash. The trim-and-fill method indicated that the results were reliable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EGFRIs have a high possibility of increasing the risk of rashes. Prevention and early treatment of rashes could be performed earlier for Asian patients who use EGFR mAbs in combination with radiotherapy and chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>System Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/<\/jats:ext-link>\n                      , identifier CRD420251039464.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1814337","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:35:50Z","timestamp":1787290550000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rash associated with epidermal growth factor receptor inhibitors: a systematic review and meta-analysis of 194 randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Fangmin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Nutrition, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyi","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaochenxi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijin","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(21)00134-x","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Cancer Network JNCCN"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-012-0007-2","article-title":"Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA","volume":"16","author":"Lyseng-Williamson","year":"2012","journal-title":"Mol Diagnosis Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines(\u2729)","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Supportive Care Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.749789","article-title":"Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors","volume":"16","author":"Ray","year":"2013","journal-title":"J Med Econ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33225","article-title":"Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)","volume":"148","author":"Assenat","year":"2021","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2414897","article-title":"Survival outcomes of nonsmall cell lung cancer patients treated with afatinib who are affected by early adverse events","volume":"2021","author":"Logan","year":"2021","journal-title":"J Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00979","article-title":"Intermittent or continuous panitumumab plus fluorouracil, leucovorin, and irinotecan for first-line treatment of RAS and BRAF wild-type metastatic colorectal cancer: the IMPROVE trial","volume":"43","author":"Avallone","year":"2025","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.008","article-title":"Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial","volume":"17","author":"Piccirillo","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02868-1","article-title":"Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team","volume":"30","author":"Iimura","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118146","article-title":"A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"123","author":"Gawli","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.20048","article-title":"Heterogeneity testing in meta-analysis of genome searches","volume":"28","author":"Zintzaras","year":"2005","journal-title":"Genet Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2019.1634089","article-title":"Skin toxicities with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials","volume":"37","author":"Sun","year":"2019","journal-title":"Cancer Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0180","article-title":"Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2016","journal-title":"Future Oncol (London England)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70452-8","article-title":"Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial","volume":"15","author":"Ramalingam","year":"2014","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1179\/1973947813Y.0000000155","article-title":"Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials","volume":"26","author":"Qi","year":"2014","journal-title":"J Chemotherapy (Florence Italy)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/01243894-200610000-00014","article-title":"Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study","volume":"1","author":"Chang","year":"2006","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","article-title":"Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset","volume":"14","author":"Cho","year":"2019","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4143\/crt.2023.453","article-title":"Lazertinib versus gefitinib as first-line treatment for EGFR-mutated locally advanced or metastatic NSCLC: LASER301 Korean subset","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12723","article-title":"Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: subgroup analysis of LUX-Lung 3","volume":"106","author":"Kato","year":"2015","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14384","article-title":"Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer","volume":"111","author":"Nishio","year":"2020","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215577810","article-title":"Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics","volume":"22","author":"Chung","year":"2016","journal-title":"J Oncol Pharm Practice: Off Publ Int Soc Oncol Pharm Practitioners"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5437090","DOI":"10.1155\/2024\/5437090","article-title":"Protein kinase inhibitors indicated for lung cancer: pharmacodynamics, pharmacokinetics, adverse drug reactions, and evaluation in clinical trials","volume":"2024","author":"Bordet","year":"2024","journal-title":"J Clin Pharm Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1211522","article-title":"The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity","volume":"32","author":"Boccellino","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5114\/wo.2013.38566","article-title":"Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer","volume":"18","author":"Krawczyk","year":"2014","journal-title":"Contemp Oncol (Poznan Poland)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2425","article-title":"A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid Malignancies","volume":"16","author":"Kuenen","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08923973.2022.2112222","article-title":"A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis","volume":"45","author":"Liu","year":"2023","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000486338","article-title":"Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis","volume":"94","author":"Petrelli","year":"2018","journal-title":"Oncology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.06.001","article-title":"Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus","volume":"96","author":"Russi","year":"2015","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.critrevonc.2017.10.011","article-title":"Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: a systematic review","volume":"120","author":"Bonomo","year":"2017","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review","volume":"22","author":"Yuan","year":"2023","journal-title":"J Cosmetic Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14728","article-title":"Persistent alteration of the skin microbiome in patients with skin rash after receiving EGFR inhibitor treatment","volume":"32","author":"Ashida","year":"2023","journal-title":"Exp Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"eaax2693","DOI":"10.1126\/scitranslmed.aax2693","article-title":"Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy","volume":"11","author":"Klufa","year":"2019","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/ol.2022.13649","article-title":"Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: a systematic review and meta-analysis","volume":"25","author":"Obradovic","year":"2023","journal-title":"Oncol Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:35:51Z","timestamp":1787290551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1814337"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1814337","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1814337"}}